Integrating Regenerative Therapies and Artificial Intelligence for Precision Management of Diabetic Foot Ulcers

Future direction

The integration of NDDSs into diabetic wound healing represents a transformative advancement, offering precise, sustained, and localized delivery of therapeutic agents. By overcoming many of the limitations associated with conventional treatment methods, NDDSs have the potential to significantly improve clinical outcomes. However, despite these promising developments, several challenges must be addressed to fully realize their therapeutic potential.

One of the primary challenges lies in optimizing delivery systems to ensure proper spatial and temporal control over growth factors and gene therapies. The healing process of diabetic wounds is highly dynamic, requiring finely tuned therapeutic interventions at different stages. Uncontrolled release of bioactive molecules may lead to suboptimal effects or even adverse outcomes. Therefore, innovative delivery platforms capable of stimuli-responsive or sustained release mechanisms are crucial for maximizing the benefits of NDDSs in wound healing. Another critical aspect is the stability and bioavailability of therapeutic agents. Many bioactive compounds, such as curcumin, EGF, and exosomes, suffer from rapid degradation, poor solubility, or inefficient cellular uptake, which limits their therapeutic impact. Advanced nanocarrier designs, including polymeric nanoparticles, lipid-based vesicles, and hydrogel-based matrices, have been explored to enhance drug stability and pharmacokinetics. However, further research is needed to refine these strategies and ensure consistent bioactivity throughout the healing process.

The variable outcomes observed in regenerative therapies involving growth factors, exosomes, and NDDSs largely stem from inconsistent bioavailability, premature degradation, and poor spatiotemporal control of therapeutic release. These limitations underscore the urgent need for the development of stimuli-responsive nanocarriers capable of precise and sustained delivery in response to specific biological cues—such as pH, redox potential, or enzymatic activity—within the regenerative microenvironment. Such smart delivery systems can dynamically regulate the bioactivity of therapeutic molecules, minimize off-target effects, and enhance retention at the defect site, thereby improving overall therapeutic efficacy. Equally important is the standardization of hydrogel and nanoparticle formulations to ensure reproducibility and comparability across studies. Variations in polymer composition, cross-linking density, particle size distribution, and encapsulation efficiency significantly influence the pharmacokinetics and mechanobiological behavior of the delivery system. Establishing consensus on characterization metrics, QC parameters, and reporting standards will be essential to advance the clinical translation of these regenerative modalities. Harmonized protocols supported by regulatory-compliant analytical frameworks will not only enhance interlaboratory reproducibility but also facilitate regulatory approval processes. Ultimately, integrating stimuli-responsive nanocarriers with standardized hydrogel scaffolds represents a promising convergence of materials science and regenerative biology. This approach enables controlled therapeutic release, supports tissue-specific regeneration, and bridges the translational gap between bench-scale innovations and clinically viable regenerative therapies.

Balancing safety and efficacy is also a major concern, particularly in the context of siRNA and miRNA therapies. While these genetic interventions offer precise regulatory control over wound-healing pathways, the risk of off-target effects, immune activation, and unpredictable gene silencing poses significant hurdles to their clinical application. To mitigate these risks, NDDS formulations must incorporate biocompatible, nonimmunogenic materials while leveraging targeting strategies to improve specificity and minimize unintended consequences. Moreover, the clinical translation of NDDS-based therapies, particularly exosome-based treatments, faces significant scalability challenges. The efficient manufacturing, storage, and QC of nanoparticle formulations, hydrogel-based carriers, and engineered exosomes remain key bottlenecks in large-scale production. Ensuring batch-to-batch consistency and cost-effective production methods will be crucial for bringing these therapies from the laboratory to clinical practice.

In this review, clinical investigations provide the most translationally relevant evidence for DFU management, showing that recombinant growth factors, exosome-based therapeutics, and targeted revascularization effectively promote granulation, angiogenesis, and epithelialization. Nonetheless, heterogeneity in wound etiology, metabolic control, and patient comorbidities continues to limit reproducibility and therapeutic predictability. Establishing multicenter clinical trials and standardized biomarker panels is therefore essential to confirm efficacy and long-term safety. In contrast, preclinical studies have elucidated key regenerative mechanisms—such as SIRT3/SOD2-dependent mitochondrial restoration and macrophage–keratinocyte exosomal signaling—that underpin tissue repair. However, the structural and physiological disparities between rodent and human skin, particularly in immune regulation and chronicity of inflammation, constrain translational fidelity. To bridge this gap, future animal models should incorporate ischemic, neuropathic, and infectious elements reflective of the clinical DFU microenvironment.

The integration of AI-based patient stratification, semi-supervised learning, and federated data frameworks offers a pathway to harmonize mechanistic and clinical insights, enhancing predictive accuracy and therapeutic personalization. Collectively, while animal models remain vital for mechanistic exploration, human studies provide the cornerstone for clinical translation, steering DFU treatment toward intelligent, precision-guided regenerative medicine.

AI-based wound-assessment tools have advanced rapidly in recent years; however, their clinical integration remains constrained by the absence of unified benchmarks and validation frameworks across heterogeneous datasets. Most existing models are trained on limited, single-institution datasets that lack demographic diversity, standardized image capture protocols, and consistent annotation schemes, resulting in reduced generalizability and biased diagnostic outcomes. To overcome these barriers, the establishment of open-access, multi-institutional, and expertly annotated datasets encompassing DFU imaging (RGB, hyperspectral, thermal) and sensor-derived data is essential. These datasets should capture variations in ethnicity, skin tone, wound stage, and comorbidity to ensure equitable model performance across populations.

Furthermore, standardized performance metrics—such as sensitivity, specificity, accuracy, precision, recall, and F1 score—must be universally adopted to enable objective benchmarking and transparent comparison among studies. Implementing such uniform evaluation criteria would facilitate the reproducibility of algorithmic results and accelerate regulatory review. In parallel, the development of formal regulatory frameworks under agencies such as the U.S. Food and Drug Administration (FDA) and the European Conformity (CE) pathways is imperative to guide ethical approval, post-market surveillance, and clinical reliability of AI-based wound care systems. In summary, open-access data resources, harmonized performance metrics, and regulatory oversight will foster robust, interoperable, and trustworthy AI tools capable of delivering clinically validated, real-world impact in DFU management.

The absence of unified benchmarks and formal approval pathways for AI-based wound care systems impedes clinical adoption, comparability, and regulatory trust. A rigorous evaluation framework should mandate standardized performance metrics reported with confidence intervals and predefined clinical thresholds. At minimum, studies should disclose accuracy, sensitivity, specificity, and F1 score, alongside area under the ROC/PR curves for imbalanced datasets; calibration indices (e.g., Brier score, calibration slope/intercept); decision-curve analysis for net clinical benefit; and failure analysis stratified by wound etiology, Fitzpatrick skin type, comorbidities, and imaging conditions. External, multisite validation and prospective testing must be required to demonstrate transportability and mitigate dataset shift.

Regulatory engagement should follow established Software as a Medical Device (SaMD) paradigms. In the United States, developers should institute an ISO 13485-compliant quality management system with documented risk management (ISO 14971), software lifecycle controls (IEC 62304), cybersecurity (e.g., SBOMs, vulnerability handling), and human-factors engineering (IEC 62366). Early interaction with FDA through Q-Submission can clarify benefit–risk claims, reference standards, and clinical evidence needs, including whether a 510(k), de novo, or PMA route is appropriate. For adaptive models, sponsors should predefine change protocols (e.g., data governance, monitoring triggers, retraining boundaries, and verification/validation gates) and align them with Good Machine Learning Practice and real-world performance plans.

For CE marking under the EU MDR, manufacturers should establish a conformity strategy with a notified body: device classification and intended use, state-of-the-art comparison, clinical evaluation per MEDDEV/MDR, and post-market clinical follow-up. Harmonized standards (ISO 13485, ISO 14971, IEC 62304, IEC 82304-1) and transparent technical documentation (intended purpose, datasets, metrics, bias and fairness analyses, human oversight) should be integral.

Post-market, both FDA and CE pathways require active surveillance: continuous real-world performance monitoring, drift and bias detection, periodic safety update reports, complaint/incident handling, cybersecurity patching, and prespecified action limits for model rollback or retraining. Together, standardized metrics, proactive regulatory dialogue, and lifecycle safety oversight can convert promising prototypes into clinically reliable, ethically governed wound-care AI.

Despite rapid progress, AI has not yet been fully integrated into therapeutic decision-making or drug delivery systems. Future developments should focus on AI-guided, stimuli-responsive drug-release platforms that dynamically adjust therapeutic delivery according to wound microenvironmental cues—such as pH, temperature, oxygenation, or inflammatory biomarkers. These intelligent nanoplatforms could autonomously modulate the release kinetics of growth factors, peptides, or exosomes in response to real-time physiological changes, thereby maintaining an optimal healing niche.

Moreover, the convergence of wearable biosensors and AI analytics offers a powerful framework for real-time therapeutic feedback and precision control. By continuously monitoring biochemical and biophysical parameters—such as moisture, cytokine levels, or perfusion indices—wearable systems can feed data into adaptive AI algorithms capable of recalibrating dosing, frequency, and modality of treatment in situ. This closed-loop, patient-specific management system transforms wound care from a reactive to a predictive paradigm.

Finally, digital twin technologies represent the next frontier in AI-assisted regenerative medicine. By generating virtual patient replicas based on multiomic, imaging, and physiological datasets, digital twins can simulate individualized wound-healing trajectories, predict therapeutic outcomes, and optimize intervention timing. The integration of such AI-empowered simulation models with biosensor-guided drug delivery will accelerate the realization of intelligent, self-regulating, and precision-oriented wound-regeneration systems—marking a decisive step toward data-driven, adaptive therapeutics in clinical practice.

To strengthen the Digital Twin section, it is essential to explicitly address the ethical foundations governing data ownership, privacy, and informed consent when generating virtual patient replicas. Digital Twin models rely on continuous multimodal data streams—including imaging, biosensor outputs, and molecular biomarkers—to simulate individualized wound-healing trajectories. However, the creation and operation of such high-fidelity virtual replicas introduce substantial ethical risks that remain insufficiently discussed. We therefore recommend incorporating a dedicated subsection outlining the governance mechanisms required to safeguard patient data rights.

First, data ownership must be defined within a legal–ethical framework specifying who controls, accesses, and benefits from the Digital Twin. Patients should retain clear ownership of their raw physiological and imaging data, while processed data and model derivatives must be governed by transparent custodial agreements. Second, informed consent should be reconceptualized as a dynamic, ongoing process rather than a one-time authorization. Because digital twins continuously evolve as new biosensor and clinical data are ingested, patients must be able to modify or withdraw consent as model functions expand. Third, strong data-protection measures—including FL, differential privacy, and secure multiparty computation—should be implemented to minimize re-identification risk during model development and cross-institutional collaboration. These safeguards align with the responsible AI principles highlighted elsewhere in this work, in which patient-generated data are filtered, summarized, and escalated only when clinically meaningful deviations occur. Finally, Digital Twin deployment must incorporate auditable oversight mechanisms with clinician-in-the-loop governance to ensure that predictive outputs do not override human clinical judgment. Embedding these ethical, legal, and regulatory protections will ensure that Digital Twin technologies advance precision wound care while upholding patient autonomy, privacy, and data sovereignty.

A major limitation in current AI-driven wound assessment and prediction models lies in their reliance on small, single-institution datasets, which inherently restrict model generalizability and clinical applicability across diverse patient populations. Models trained on homogeneous datasets often fail to account for variations in ethnicity, age, comorbidities, imaging modalities, and clinical workflows—factors that profoundly influence wound morphology and healing dynamics. Consequently, these models may exhibit strong internal validity but limited external robustness when applied in real-world, multicenter clinical settings.

To address this issue, the development of open-access, multi-institutional datasets with broad demographic representation and standardized imaging protocols is imperative. Harmonization of image capture parameters—such as lighting, resolution, angle, and calibration—alongside uniform metadata annotation (e.g., wound type, stage, infection status, and treatment history) can significantly enhance interoperability and cross-study comparability. Such large-scale, well-curated datasets would enable the benchmarking of algorithmic performance and promote reproducibility across research groups, thereby accelerating the regulatory readiness of AI tools for clinical deployment. Furthermore, emerging FL frameworks and privacy-preserving computation paradigms (e.g., differential privacy, homomorphic encryption, and secure multiparty computation) provide a transformative pathway for collaborative model development without the need to exchange raw patient data. By allowing institutions to train models locally while sharing only model parameters or gradients, FL enables the integration of distributed datasets into robust, generalizable AI systems that respect patient confidentiality and comply with ethical and legal standards such as GDPR and HIPAA.

Integrating these federated and privacy-aware infrastructures with standardized, demographically diverse wound image repositories could revolutionize predictive modeling in wound care. This approach promotes data equity, enhances model transparency, and ensures that AI systems are trained under clinically realistic, globally inclusive conditions. Ultimately, such a strategy will bridge the translational gap between algorithmic innovation and clinical reliability, paving the way for scalable, ethical, and precision-driven AI applications in regenerative and wound medicine.

As wearable biosensors and smart dressings (e.g., PETAL platforms) become increasingly integrated into AI-enabled wound monitoring, future research must systematically address a critical yet underexamined barrier to clinical translation: biocompatibility and the high incidence of Medical Adhesive–Related Skin Injury (MARSI) in elderly diabetic patients. Age-related dermal thinning, impaired microcirculation, neuropathy, and delayed inflammatory resolution substantially elevate the risk of epidermal stripping, skin tears, and irritant dermatitis during repetitive device application and removal. These vulnerabilities are especially pronounced in DFU populations, who often require long-term, continuous monitoring in home-care settings.

To ensure safe adoption of wearable diagnostics, next-generation smart dressings must incorporate low-trauma adhesion technologies, including silicone-based, hydrocolloid, or hybrid atraumatic adhesives with controlled peel force and moisture-balanced interfaces. Equally essential are standardized protocols for device placement, removal, and rotation, supported by barrier-film conditioning, gentle-angle detachment procedures, and routine periwound skin assessments to detect early erythema, maceration, or shear-related microinjury. Embedding microtextured, breathable adhesive matrices may further reduce shear stress and humidity accumulation—two major contributors to MARSI. AI-driven platforms should be designed not only to interpret biochemical and biophysical wound markers but also to monitor adhesive–skin interactions. By analyzing temporal patterns of localized redness, temperature elevation, or moisture retention beneath the dressing, adaptive algorithms could autonomously flag early MARSI risk and recommend repositioning schedules, switching adhesive types, or reducing wear time. In addition, interoperability between patient-facing mobile applications and clinician dashboards can facilitate remote supervision, enabling timely intervention before clinically significant skin injury develops.

Ultimately, incorporating MARSI-aware biodesign principles, evidence-based home-care protocols, and AI-supported safety monitoring will be essential for the responsible, equitable translation of wearable wound technologies. Addressing these biocompatibility challenges will significantly enhance patient adherence, reduce complications, and strengthen the clinical value of AI-enabled, multimodal sensing ecosystems in DFU management.

As DL-based wound assessment models continue to advance, a critical next step for clinical translation is the integration of robust explainable AI (XAI) frameworks that enhance interpretability for frontline health care providers. While DL architectures can achieve high accuracy in distinguishing nonhealing versus infected wounds, their “black-box” nature limits clinical trust and hinders adoption in routine wound-care workflows, particularly among nursing staff who are responsible for daily wound evaluation and escalation of care.

Future development should prioritize XAI mechanisms capable of producing clear, human-interpretable visualizations that map the model’s decision-making process onto clinically meaningful wound features. Techniques such as class activation maps, Grad-CAM, saliency heatmaps, and feature-attribution overlays can highlight regions of concern—such as increased exudate, erythema borders, slough accumulation, or necrotic patches—and allow nursing staff to verify whether AI predictions align with visual cues observed at the bedside. These visualization tools not only support diagnostic transparency but also provide actionable insights, enabling nurses to more confidently triage wounds that require debridement, antimicrobial therapy, or specialist consultation. In addition, integrating XAI outputs into user-friendly dashboards within remote monitoring platforms can facilitate seamless communication between AI systems and clinical practitioners. For instance, heatmap-guided alerts could be paired with standardized wound-assessment terminology, allowing nursing personnel to rapidly interpret model outputs in home-care or telehealth settings. Future work should also evaluate the usability of these XAI interfaces across varying levels of digital literacy among health care providers, ensuring equitable and safe deployment.

By embedding interpretable, evidence-aligned visualization methods into DL-based wound classification systems, AI technologies can transition from being high-performance research tools to clinically trustworthy decision-support systems, ultimately strengthening their integration into nursing workflows and improving outcomes in diabetic wound management.

Integrative framework linking regenerative biology and AI-driven precision monitoring

A unified framework that tightly integrates regenerative biology with AI-driven analytics is essential for translating DFU management from parallel technological efforts into a coherent precision-medicine ecosystem. Regenerative interventions—such as NDDS-mediated cytokine regulation and exosome-based delivery of pro-healing nucleic acids—produce quantifiable biomarker trajectories that can be transformed into predictive AI signatures. These include dynamic changes in TEWL, cytokine gradients, ECM remodeling indicators, and transcriptomic states that collectively reflect the biological responsiveness of the wound microenvironment. When encoded as temporal feature vectors, such multimodal biomarkers provide a mechanistically meaningful substrate for ML models capable of forecasting healing probability, stratifying patients by expected therapeutic response, and identifying early deviations suggestive of treatment failure.

AI systems further enable objective validation of regenerative therapy by integrating molecular signals with serial imaging assessments. High-frequency wound imaging—capturing granulation patterning, perfusion asymmetry, and tissue optical characteristics—can be correlated with molecular and transcriptomic shifts to construct composite response curves. These cross-modal correlations allow AI to confirm whether biological effects induced by NDDS or exosome therapies are translating into measurable structural improvement, thereby overcoming the limitations of purely clinical inspection. Such integration naturally establishes a biologically informed feedback loop, in which continuous monitoring feeds real-time data into adaptive inference models. These models can recommend adjustments in regenerative treatment intensity, timing, or modality based on predicted healing trajectories and emerging biomarker patterns. By merging TEWL measurements, cytokine panels, imaging features, and transcriptomic signatures into a standardized inference pathway, the resulting analytics pipeline functions as a clinically usable predictive tool—one capable of supporting precision dosing, early intervention, and personalized therapy planning. Collectively, this integrative perspective delineates a robust translational pathway in which regenerative therapeutics and AI-enabled monitoring operate synergistically, enabling DFU management to evolve toward a data-rich, adaptive, and biologically grounded precision-care paradigm.

An integrative framework that couples regenerative biology with AI-driven precision monitoring offers a compelling conceptual pathway toward next-generation management of chronic DFUs. However, a rigorous translational perspective requires clear differentiation between mechanistic efficacy demonstrated in preclinical systems and therapeutic benefit substantiated by human clinical evidence, particularly for advanced regenerative modalities such as EVs and direct tissue reprogramming.

EV-based therapies have generated substantial enthusiasm due to their capacity to deliver miRNAs, proteins, and metabolic regulators that modulate angiogenesis, inflammation, mitochondrial function, and ECM remodeling. In rodent and in vitro models, EVs derived from mesenchymal or epithelial lineages consistently accelerate re-epithelialization, enhance vascular density, and attenuate oxidative stress. Nevertheless, these effects remain context-dependent and highly variable, influenced by EV source, isolation method, cargo heterogeneity, dosing metrics, and delivery route. Importantly, robust clinical evidence demonstrating durable superiority over standard DFU care is still lacking. To date, most human studies remain exploratory or early phase, with limited sample sizes, heterogeneous endpoints, and insufficient longitudinal follow-up to establish reproducibility, dose–response relationships, or long-term safety. Thus, while EVs represent a biologically elegant and potentially scalable cell-free modality, their current status should be regarded as translationally immature rather than clinically established.

A similar distinction applies to direct tissue reprogramming strategies, which aim to convert resident fibroblasts or stromal cells into endothelial, neural, or lymphatic lineages in situ. These approaches address fundamental DFU pathologies—ischemia, neuropathy, and impaired immune drainage—at a mechanistic level that conventional wound dressings cannot reach. Preclinical studies demonstrate impressive restoration of perfusion, axonal regeneration, and microenvironmental homeostasis. However, clinical translation remains speculative, constrained by unresolved challenges in delivery efficiency, spatial control, off-target lineage conversion, and long-term genomic or epigenomic safety. At present, no large-scale human trials have validated the safety or efficacy of in vivo reprogramming for DFUs, underscoring the gap between conceptual innovation and regulatory readiness.

Within this context, AI-driven precision monitoring should not be framed as a validation shortcut for regenerative therapies, but rather as an objective adjudication layer that can expose the discrepancy between molecular activation and true clinical benefit. By integrating longitudinal imaging, functional biomarkers (e.g., TEWL, perfusion asymmetry), and molecular readouts into unified inference models, AI systems can distinguish transient biological signals from sustained tissue recovery. Crucially, such platforms enable comparative effectiveness assessment, benchmarking regenerative interventions against established standards of care—including debridement, off-loading, revascularization, and infection control—rather than evaluating them in isolation.

Therefore, the value of this integrative framework lies not in amplifying optimism, but in enforcing evidence stratification. Regenerative therapies should be positioned along a continuum of translational maturity, with AI serving as a rigor-enhancing tool to (i) identify responder phenotypes, (ii) quantify real-world durability of biological effects, and (iii) define failure modes early in development. Only through this critical, data-anchored integration can regenerative biology advance from mechanistic promise toward reproducible, clinically actionable therapy within DFU care.

Translational barriers: clinical, regulatory, and manufacturing considerations

Although emerging NDDS platforms, exosome therapeutics, and AI-enabled wound-assessment tools show substantial mechanistic promise, their clinical translation remains constrained by several structural limitations. Most regenerative biologics for DFU are supported only by early-phase or preclinical studies, with a lack of Phase II/III trials to establish dose–response relationships, long-term safety, and superiority over standard interventions such as debridement, off-loading, revascularization, and infection control. Regulatory pathways add significant complexity: exosome and gene-modulating nanocarriers frequently fall under ATMP, MDR, or FDA CBER frameworks requiring rigorous CMC documentation, validated potency assays, and robust sterility and stability data, while AI-based systems must fulfill SaMD requirements for external validation, drift monitoring, and human-factors engineering. Manufacturing bottlenecks further hinder clinical feasibility, as EV production suffers from batch variability, inconsistent cargo potency, and high costs due to labor-intensive purification processes and immature GMP pipelines; similarly, NDDS formulations struggle with the reproducibility of nanoparticle attributes essential for quality-by-design compliance. At the digital front, AI wound-analysis models—often trained on single-center, demographically narrow datasets—frequently fail to generalize across populations, imaging devices, and workflows, leading to algorithmic bias and poor external validity. These translational gaps collectively underscore the need for harmonized clinical endpoints, multicenter datasets, scalable and automated bioprocessing, standardized EV and NDDS quality attributes, and regulatory-ready AI validation frameworks to enable safe, reliable, and economically viable integration of next-generation regenerative and digital technologies into real-world DFU care. As summarized in Table 4, the management of diabetic foot ulcers and diabetes care has undergone a progressive paradigm shift, evolving from conventional clinical approaches to AI-enabled regenerative precision medicine.

Concluding remarks

This article presents a structured approach to science communication, transforming complex biomedical AI concepts into an accessible, narrative-based format. Set in Taiwan in 2035, it follows Mr. Da-Ming Wang, an elderly diabetic patient in a semi-rural area who experiences next-generation AI-assisted wound care. Through his journey, advanced computational systems are portrayed as integrated, human-centered tools in clinical decision-making. The framework is organized into three tiers: foundations, core techniques, and applications. The foundations tier covers Data Engineering and Preprocessing (DEP), Knowledge Representation and Reasoning (KRR), and Symbolic AI, which establish the interpretive base of biomedical intelligence. The core techniques tier includes expert systems, ML, DL, and XAI, enabling prediction and transparent reasoning. The applications tier brings these into clinical reality through NLP, computer vision (CV), robotics, and distributed AI multi-agent systems (DAI-MAS), under ethical and regulatory guidance. By embedding this framework in Mr. Da-Ming Wang’s story, the article bridges computation and compassion, illustrating how AI can enhance precision and safety while preserving the human essence of care (Box 1). ⁴⁴

The present review underscores that, although DFU research now spans diverse scientific frontiers—including molecular wound biology, nanotechnology, stem cell and EV therapeutics, GMP manufacturing, gene editing, multispectral imaging, thermal sensing, and advanced AI analytics—the resulting conceptual breadth risks diluting clinical depth. By synthesizing these scattered domains through a more clinically anchored lens, several unifying principles emerge. First, when benchmarked against standard DFU care, regenerative nanotherapies and AI-driven diagnostic systems demonstrate clear mechanistic promise but remain unevenly validated in human populations. Most efficacy data for NDDSs, growth factors, or exosome-based interventions originate from rodent models whose inflammatory dynamics, vascular architecture, and chronicity do not fully recapitulate human DFUs, thereby limiting translational predictability. Likewise, AI platforms trained on institution-specific datasets lack the external validation, workflow integration, and interpretability required for dependable clinical deployment.

A refined synthesis therefore highlights the need to transition from mechanistic enumeration toward clinically meaningful evaluation—specifically, how emerging technologies improve healing trajectories, diagnostic sensitivity, or decision-making compared with current standards such as sharp debridement, pressure off-loading, infection control, and revascularization. NDDSs and exosome-based therapeutics must be assessed through harmonized potency metrics, dose–response relationships, and reproducible human trial endpoints. Similarly, AI systems should be positioned not as standalone solutions but as clinician-supervised tools embedded within real-world workflows, providing actionable trend detection, early deterioration alerts, and objective comparison against established DFU management guidelines.

Looking forward, true innovation lies in bridging existing evidence gaps. This requires (i) multicenter clinical trials that align mechanistic advances with patient-centered outcomes; (ii) translational animal models that more accurately mirror ischemic, neuropathic, and infectious dimensions of human DFUs; (iii) standardized datasets and validation protocols for AI-driven wound assessment; and (iv) comparative studies quantifying the added value of regenerative or AI-assisted platforms relative to conventional care. By consolidating mechanistic insights into clinically grounded frameworks, next-generation NDDSs, exosome therapeutics, and AI-enabled sensing can evolve from fragmented technological innovations into coherent, evidence-based strategies. Ultimately, such integration will accelerate the development of precision, scalable, and clinically actionable solutions capable of transforming DFU management in real-world practice.

Innovation

This study introduces a transformative paradigm integrating NDDSs, stem cell–derived EVs, and AI-enabled sensing for precision diabetic wound management. By uniting regenerative nanotherapeutics with DL-driven image analytics and wearable biosensors, it enables real-time wound profiling, adaptive drug release, and predictive healing assessment. This closed-loop platform transcends conventional treatment boundaries, establishing an intelligent regenerative ecosystem that bridges molecular therapeutics and digital diagnostics—advancing DFU care toward proactive, personalized, and data-guided regeneration.